Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470496 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4765360 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL28781368 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL28472787 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4361492 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL1123659 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL30475134 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL2691990 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL4255348 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 | |
| SCHEMBL2691404 | 1.00 | CES2 (0.58) | CES2NAAAEPHX1FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | claimed |
| CN-117323278-A | Hair loss prevention nursing agent and preparation method thereof | 白银热玛三肽细胞食物科技有限公司 | 2024-01-02 | — | — | CN | claimed |
| EP-4112049-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | Fukang (Shanghai) Health Technology Co., Ltd. (CN) | 2023-01-04 | — | — | EP | claimed |
| CN-113288892-B | Use of poly ADP-ribose polymerase inhibitors against coronaviruses | 甫康（上海）健康科技有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-117323278-A | Hair loss prevention nursing agent and preparation method thereof | 白银热玛三肽细胞食物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-4112049-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | Fukang (Shanghai) Health Technology Co., Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-107849017-B | 1,1, 1-trifluoro-3-hydroxypropan-2-ylcarbamate derivatives and 1,1, 1-trifluoro-4-hydroxybutyl-2-ylcarbamate derivatives as MAGL inhibitors | 辉瑞公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-107849017-A | 1,1, 1-trifluoro-3-hydroxypropan-2-ylcarbamate derivatives and 1,1, 1-trifluoro-4-hydroxybutyl-2-ylcarbamate derivatives as MAG L inhibitors | 辉瑞公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-103554107-B | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | 艾伯维巴哈马有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-104125960-A | Derivatives of aza adamantane and uses thereof | CONNEXIOS LIFE SCIENCES PVT LTD | 2014-10-29 | — | — | CN | disclosed |
| CN-1029403-C | 2-oxo-1-oxa-8-azaspiro [4,5] decane derivatives, pharmaceutical compositions containing them and process for preparing same | RICHTER GEDEON VEGYESZET (HU) | 1995-08-02 | — | — | CN | disclosed |
| EP-0441807-B1 | LIQUID PHASE FLUORINATION | EXFLUOR RES CORP (US) | 1995-03-22 | — | — | EP | disclosed |
| US-5332790-A | Liquid-phase fluorination | EXFLUOR RESEARCH CORPORATION (US) | 1994-07-26 | — | — | US | disclosed |
| US-5322904-A | Liquid-phase fluorination | EXFLUOR RESEARCH CORPORATION (US) | 1994-06-21 | — | — | US | disclosed |
| US-5322903-A | Liquid-phase fluorination | EXFLUOR RESEARCH CORPORATION (US) | 1994-06-21 | — | — | US | disclosed |
| US-5093432-A | Perfluorination of esters or ethers | EXFLUOR RESEARCH CORPORATION (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0441807-A1 | LIQUID PHASE FLUORINATION. | EXFLUOR RES CORP (US) | 1991-08-21 | — | — | EP | disclosed |
| CN-1049348-A | New 2-oxo-1-oxa--8-azaspiro [4,5] decane derivative contains their pharmaceutical composition and preparation method thereof | RICHTER GEDEON VEGYESZET (HU) | 1991-02-20 | — | — | CN | disclosed |
| WO-1990003353-A1 | LIQUID PHASE FLUORINATION | EXFLUOR RESEARCH CORPORATION (US) | 1990-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | CES2 3503/4885NAAA 1540/4885EPHX1 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.